In short
Clinical trials are investigating Urapidil in people with acute ischemic stroke. The main goal is to compare blood pressure management strategies after mechanical thrombectomy and measure recovery at 90 days. The study looks at whether a protocol using Urapidil can improve outcomes in this target group.
Key points
- Clinical trials investigating Urapidil in the provided data focus on acute ischemic stroke. The HOPE study tested blood pressure management after mechanical thrombectomy, comparing standard care with a protocol based on hemodynamic optimization. It was a Phase 3 interventional trial with 814 participants. The main outcome was the modified Rankin Scale at 90 days after randomization. The study is listed as completed.
Trial overview
The available trial data describe the HOPE study, which investigated Urapidil in people with acute ischemic stroke. This was an interventional study, meaning the researchers assigned treatment strategies and then compared the results. The study is listed as completed and included 814 participants.
Study design and treatment groups
The trial compared standard blood pressure management after mechanical thrombectomy with a protocol aimed at hemodynamic optimization. In simple terms, the study asked whether a more tailored blood pressure strategy could improve recovery after the clot-removal procedure. The intervention list shows Urapidil as one of the study drugs used intravenously in the trial.
Who participated
The target population was people with acute ischemic stroke who had undergone mechanical thrombectomy. The source data do not provide more detailed entry rules, such as age limits or other selection criteria.
Main outcome measured
The primary outcome was the modified Rankin Scale (mRS) score at 90 days after randomization. This scale is used to measure disability and daily function after stroke, so it helps show how well participants recovered. The analysis planned a direct comparison between the two groups using an intention-to-treat analysis and a shift analysis of mRS scores, with the main effect reported as an odds ratio and 95% confidence interval.
What the study setup means for patients
This trial was designed to see whether blood pressure control after thrombectomy could be improved by matching targets to the level of vessel reopening, also called recanalization. The focus was not on long-term drug use, but on treatment decisions made during the stroke care period. For patients and families, the key point is that the study tested whether a more personalized blood pressure plan could lead to better recovery after stroke.